Acadia Pharmaceuticals (ACAD) is down -11.2%, or -$2.63 to $20.96.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACAD:
- Positive Outlook for ACADIA Pharmaceuticals Despite Setbacks: Buy Rating Justified
- Video: Lithium Americas jumps amid talks with DOE, General Motors on loan
- Morning Movers: uniQure skyrockets after AMT-130 trial meets primary endpoint
- Balanced Hold Rating for ACADIA Pharmaceuticals Amid Trial Setback and Growth Potential
- Morgan Stanley sees ‘small impact’ on Acadia valuation from ACP-101 failure